See more : Canlan Ice Sports Corp. (ICE.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jiangsu Bioperfectus Technologies Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Voquz Labs AG (VQLA.VI) Income Statement Analysis – Financial Results
- TDC SOFT Inc. (TDCSF) Income Statement Analysis – Financial Results
- Trust-Search Corp.,Ltd. (3115.TWO) Income Statement Analysis – Financial Results
- PT Sarana Menara Nusantara Tbk. (TOWR.JK) Income Statement Analysis – Financial Results
- Restaurant Brands New Zealand Limited (RTBRF) Income Statement Analysis – Financial Results
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SS)
About Jiangsu Bioperfectus Technologies Co., Ltd.
Jiangsu Bioperfectus Technologies Co., Ltd. researches and develops, produces, and sells in vitro diagnostic products in China. It offers in vitro diagnostic reagents and supporting detectors, as well as in vitro testing services. The company was founded in 2010 and is based in Taizhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 403.18M | 5.53B | 2.84B | 1.74B | 288.79M | 230.70M | 187.29M | 129.14M |
| Cost of Revenue | 253.94M | 2.18B | 876.35M | 389.86M | 52.68M | 42.28M | 32.45M | 23.66M |
| Gross Profit | 149.24M | 3.35B | 1.96B | 1.35B | 236.11M | 188.42M | 154.84M | 105.48M |
| Gross Profit Ratio | 37.02% | 60.62% | 69.13% | 77.59% | 81.76% | 81.67% | 82.67% | 81.68% |
| Research & Development | 136.18M | 185.82M | 106.64M | 72.07M | 38.56M | 26.38M | 21.41M | 14.31M |
| General & Administrative | 77.81M | 124.71M | 46.09M | 43.43M | 8.32M | 8.10M | 19.30M | 36.00M |
| Selling & Marketing | 81.73M | 422.55M | 416.73M | 297.44M | 88.23M | 79.48M | 73.19M | 49.09M |
| SG&A | 407.00M | 547.25M | 462.82M | 340.87M | 96.55M | 87.58M | 92.49M | 85.10M |
| Other Expenses | -28.88M | 161.50M | 35.33M | -2.27M | 10.01M | -319.22K | 170.70K | 5.19M |
| Operating Expenses | 514.30M | 894.58M | 604.79M | 410.67M | 145.12M | 123.20M | 109.58M | 99.93M |
| Cost & Expenses | 768.24M | 3.07B | 1.48B | 800.53M | 197.81M | 165.48M | 142.03M | 123.59M |
| Interest Income | 55.97M | 39.18M | 26.83M | 7.77M | 4.02M | 1.91M | 0.00 | 0.00 |
| Interest Expense | 7.08M | 5.33M | 3.96M | 83.13K | 83.47K | 68.52K | 0.00 | 0.00 |
| Depreciation & Amortization | 110.78M | 111.01M | 51.92M | 26.62M | 20.29M | 16.71M | 12.02M | 8.56M |
| EBITDA | -255.06M | 2.25B | 1.45B | 933.05M | 108.35M | 79.09M | 62.75M | 22.11M |
| EBITDA Ratio | -63.26% | 46.73% | 49.96% | 55.45% | 37.48% | 34.27% | 29.31% | 9.44% |
| Operating Income | -382.78M | 2.15B | 1.39B | 963.01M | 95.04M | 73.29M | 50.56M | 8.36M |
| Operating Income Ratio | -94.94% | 38.84% | 49.13% | 55.36% | 32.91% | 31.77% | 27.00% | 6.47% |
| Total Other Income/Expenses | 7.11M | -10.99M | -3.13M | -2.02M | -340.44K | -319.22K | 170.71K | 5.19M |
| Income Before Tax | -375.67M | 2.14B | 1.39B | 960.99M | 94.70M | 72.97M | 50.73M | 13.55M |
| Income Before Tax Ratio | -93.18% | 38.64% | 49.02% | 55.24% | 32.79% | 31.63% | 27.09% | 10.49% |
| Income Tax Expense | -1.86M | 310.81M | 198.56M | 141.42M | 10.94M | 9.15M | 8.06M | 5.19M |
| Net Income | -373.81M | 1.83B | 1.19B | 819.57M | 83.76M | 63.82M | 42.67M | 8.36M |
| Net Income Ratio | -92.72% | 33.03% | 42.03% | 47.11% | 29.00% | 27.67% | 22.78% | 6.47% |
| EPS | -6.38 | 31.18 | 20.36 | 13.98 | 1.43 | 1.45 | 0.97 | 0.21 |
| EPS Diluted | -6.38 | 31.18 | 20.36 | 13.98 | 1.43 | 1.45 | 0.97 | 0.21 |
| Weighted Avg Shares Out | 58.59M | 58.62M | 58.62M | 58.62M | 58.62M | 44.02M | 43.99M | 39.81M |
| Weighted Avg Shares Out (Dil) | 58.59M | 58.62M | 58.62M | 58.62M | 58.62M | 44.02M | 43.99M | 39.81M |
Source: https://incomestatements.info
Category: Stock Reports